Together, the two companies are marketing and selling the autoimmune disease drugs Dupixent and Kevzara, the cancer drugs Libtayo and Zaltrap, and the cholesterol drug Praluent. Regeneron also has a lucrative partnership with Sanofi ( NASDAQ:SNY), another life sciences and pharmaceutical company. are awarded to Regeneron, and the company splits with Bayer the revenue earned from markets outside the U.S. The biggest moneymaker for Regeneron is Eylea, an eye disease drug that the company makes in collaboration with Bayer ( OTC:BAYRY). Novavax expects to report results from a phase 1/2 study of this combo vaccine in the first half of 2022. The company is developing a combination COVID-19/flu vaccine using both NVX-CoV2373 and NanoFlu. In 2020, Novavax reported positive results from its late-stage testing of an experimental flu vaccine called NanoFlu. Novavax hopes to gain additional regulatory wins in 2022, including in the U.S. The EUL is an important prerequisite for distribution to countries that participate in the COVAX Facility, which works to ensure access to COVID-19 vaccines for low- and middle-income nations. The vaccine also received an Emergency Use Listing (EUL) from the World Health Organization. NVX-CoV2373 has already secured authorizations or approvals in the European Union, India, Indonesia, the Philippines, and South Korea. Its vaccine candidate uses a single protein molecule, known as a protein subunit, to spur an immune response against the novel coronavirus. Novavax is developing a COVID-19 vaccine candidate that it calls NVX-CoV2373. Exelixis also acquired GamaMabs Pharma’s anti-Müllerian hormone receptor 2 (AMHR2) antibody programs. It licenses from the development-stage biotech company Aurigene the right to further develop a promising early-stage cancer drug called XL102, and, from WuXi Biologics, the company licenses a panel of monoclonal antibodies. Both of these treatment combinations are targeting previously untreated RCC.Įxelixis is profitable, which enables it to use its fast-growing cash stockpile to enter into new licensing agreements and otherwise expand its drug offerings. Exelixis is also working with drugmaker Roche ( OTC:RHHBY) to evaluate a combination treatment using Cabometyx and Roche's cancer immunotherapy treatment Tecentriq. regulatory approval in early 2021 for the use of Cabometyx in combination with Bristol Myers' immunotherapy drug Opdivo. Its biggest winner by far is Cabometyx, which is approved to treat renal cell carcinoma (RCC) and hepatocellular carcinoma (HC) - the most common types of kidney cancer and liver cancer, respectively – as well as thyroid cancer.Įxelixis and biopharma company Bristol Myers Squibb ( NYSE:BMY) won U.S. ExelixisĮxelixis has four drugs that are already on the market. The revenue potential for these three drug candidates makes Axsome Therapeutics an attractive biotech stock to consider buying in 2022. Analysts think that AXS-14, if approved, could generate peak sales of between $500 million and $1 billion. alone is more than $500 million per year. The peak annual sales forecast for AXS-07 in the U.S. If approved, AXS-05 as a depression treatment could be a blockbuster drug, with peak annual sales - the highest dollar volume of sales per year projected by analysts - estimated at $2.6 billion. regulatory approval of AXS-14 for treating fibromyalgia. AXS-07 targets the treatment of migraines, and the FDA is scheduled to make an approval decision on the investigational drug in 2022. The company’s pipeline includes two other late-stage candidates. Food and Drug Administration (FDA) identified two manufacturing deficiencies in Axsome’s regulatory filing, but Axsome believes the issues are addressable and is working with the FDA to resolve them. regulatory approval for the drug to treat depression. In early 2021, the company filed for U.S. Axsome TherapeuticsĪxsome's lead drug candidate, which it calls AXS-05, targets depression, Alzheimer’s disease-related agitation, and cigarette smoking cessation. Data sources: Yahoo! Finance, company websites.

Syn stock forecast